Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway
- PMID: 33677000
- DOI: 10.1016/j.jaad.2021.01.104
Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway
Conflict of interest statement
Conflicts of interest Dr Konstantinou has served as a paid speaker for AbbVie, Eli Lilly and Company, and Novartis. Dr Jendoubi has served as a consultant with honoraria for Sanofi and Janssen. Dr Tauber has served as a paid speaker for Janssen. Dr Bulai-Livideanu has served as a consultant with honoraria and as a paid speaker for AbbVie, Eli Lilly and Company, Janssen, UCB Pharma, and Novartis. Dr Paul has received research grants and has been consultant for Almirall, Amgen, AbbVie, BMS, Boehringer, Celgene, Eli Lilly, Janssen, Leo Pharma, Merck, Mylan, Novartis, Pfizer, Pierre Fabre, Sanofi, and UCB pharma. Drs Hegazy and Bouznad have no conflicts of interest to declare.
Comment in
-
Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy.J Am Acad Dermatol. 2021 Jul;85(1):e39-e40. doi: 10.1016/j.jaad.2021.03.006. Epub 2021 Mar 4. J Am Acad Dermatol. 2021. PMID: 33676999 No abstract available.
Comment on
-
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.J Am Acad Dermatol. 2021 Apr;84(4):1059-1067. doi: 10.1016/j.jaad.2020.10.085. Epub 2020 Nov 3. J Am Acad Dermatol. 2021. PMID: 33157177 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
